ES2152421T3 - Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas. - Google Patents

Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.

Info

Publication number
ES2152421T3
ES2152421T3 ES95930151T ES95930151T ES2152421T3 ES 2152421 T3 ES2152421 T3 ES 2152421T3 ES 95930151 T ES95930151 T ES 95930151T ES 95930151 T ES95930151 T ES 95930151T ES 2152421 T3 ES2152421 T3 ES 2152421T3
Authority
ES
Spain
Prior art keywords
polisacarido
vaccines
pneumoniae
neumolisina
neumococcico
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95930151T
Other languages
English (en)
Inventor
Joseph S-C Kuo
Heesoo K Ree
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ES2152421T3 publication Critical patent/ES2152421T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE GENERAN CONJUGADOS DE POLISACARIDOS DE PROTEINA INMUNOGENICOS QUE TIENEN UN POLISACARIDO OXIDIZADO DERIVADO A PARTIR DEL POLISACARIDO CAPSULAR DE STREPTOCOCCAL PNEUMONIAE Y LA PROTEINA DE NEUMOLISINA DEL S. PNEUMONIAE QUE SE EXPRESA DE FORMA RECOMBINANTE. LA PNEUMOLISINA NO ES TOXOIDE ANTES DE SU CONJUGACION CON DICHO POLISACARIDO OXIDIZADO. LOS CONJUGADOS INMUNOGENICOS SE UTILIZAN COMO VACUNAS PARA EVITAR LAS RESPUESTAS DE ANTICUERPOS EN EL POLISACARIDO CAPSULAR DE S. PNEUMONIAE Y EN LA PNEUMOLISINA RECOMBINANTE , Y PARA INMUNIZAR CONTRA LA ENFERMEDAD CAUSADA POR S. PNEUMONIAE.
ES95930151T 1994-08-24 1995-08-10 Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas. Expired - Lifetime ES2152421T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/295,305 US5565204A (en) 1994-08-24 1994-08-24 Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections

Publications (1)

Publication Number Publication Date
ES2152421T3 true ES2152421T3 (es) 2001-02-01

Family

ID=23137126

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95930151T Expired - Lifetime ES2152421T3 (es) 1994-08-24 1995-08-10 Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.

Country Status (14)

Country Link
US (1) US5565204A (es)
EP (1) EP0778781B1 (es)
JP (1) JP3927233B2 (es)
KR (1) KR100385411B1 (es)
AT (1) ATE198051T1 (es)
AU (1) AU704450B2 (es)
CA (1) CA2198251C (es)
DE (1) DE69519634T2 (es)
DK (1) DK0778781T3 (es)
ES (1) ES2152421T3 (es)
GR (1) GR3035081T3 (es)
IL (1) IL115047A (es)
PT (1) PT778781E (es)
WO (1) WO1996005859A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165762A (en) * 1996-08-16 2000-12-26 Smithkline Beecham Corporation DNA encoding adenine phosphoribosyltransferase from Streptococcus pneumoniae
ATE348887T1 (de) * 1996-10-31 2007-01-15 Human Genome Sciences Inc Streptococcus pneumoniae antigene und impfstoffe
JP2001519817A (ja) * 1997-03-26 2001-10-23 ブリガム アンド ウイメンズ ホスピタル 糖断片生成法
ES2230687T3 (es) * 1997-04-24 2005-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Copulacion de proteinas nomodificadas con polisacaridos derivados de haloacilo o de dihaloacilo para la preparacion de vacunas que incluyen proteinas-polisacaridos.
US6676943B1 (en) 1997-04-24 2004-01-13 Regents Of The University Of Minnesota Human complement C3-degrading protein from Streptococcus pneumoniae
AU740956B2 (en) * 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
US5882898A (en) * 1997-08-29 1999-03-16 Smithkline Beecham Corporation Streptococcus pneumoniae polynucleotides which encode folyl-polyglutamate synthetase (FPGS) polypeptides
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US5861281A (en) * 1997-10-30 1999-01-19 Smithkline Beecham Corporation Lacc
US6165763A (en) * 1997-10-30 2000-12-26 Smithkline Beecham Corporation Ornithine carbamoyltransferase
US6274719B1 (en) 1998-04-24 2001-08-14 Smithkline Beecham Corporation Gcp
CA2333578C (en) * 1998-07-14 2010-11-16 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid a
US6268177B1 (en) * 1998-09-22 2001-07-31 Smithkline Beecham Corporation Isolated nucleic acid encoding nucleotide pyrophosphorylase
WO2000026359A1 (en) * 1998-11-04 2000-05-11 Smithkline Beecham Corporation ftsX
CA2366152A1 (en) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
GB9906437D0 (en) * 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
WO2001007465A1 (en) * 1999-07-22 2001-02-01 Smithkline Beecham Corporation Ga1R
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
BR0116756A (pt) * 2000-12-28 2005-01-04 Wyeth Corp Proteìna protetora recombinante de streptococcus pneumoniae e uso da mesma
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
CA2503871C (en) 2002-11-01 2012-12-11 Glaxosmithkline Biologicals S.A. An immunogenic composition for generating an immune response against polio virus
CN100443116C (zh) * 2002-11-07 2008-12-17 新纳几美国公司 治疗或预防肺炎球菌感染的组合物及其用途
MXPA05009579A (es) 2003-03-13 2005-11-17 Glaxosmithkline Biolog Sa Proceso de purificacion para citolisina bacteriana.
AU2004263135B2 (en) * 2003-08-06 2010-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
AU2004277342B2 (en) 2003-10-02 2010-12-16 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0502096D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP5792920B2 (ja) 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
MX2008009280A (es) 2006-01-17 2008-12-12 Arne Forsgren Una nueva proteina de haemophilus influenzae expuesta en la superficie (proteina e; pe).
US8414899B2 (en) 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
WO2007144647A2 (en) * 2006-06-15 2007-12-21 Timothy John Mitchell Adjuvant compositions
KR101446238B1 (ko) * 2006-08-07 2014-10-01 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 단백질 매트릭스 백신 및 그의 제조방법 및 백신 투여방법
CN110064053A (zh) * 2006-08-07 2019-07-30 哈佛大学校长及研究员协会 蛋白质基质疫苗及这种疫苗的制备和给药方法
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2008287286B2 (en) 2007-04-13 2013-10-10 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
US8226959B2 (en) * 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
EP2383035A4 (en) 2008-12-03 2017-11-22 Kaneka Corporation Formyl group-containing porous support, adsorbent using same, method for producing same, and method for producing the adsorbent
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
KR101315599B1 (ko) 2011-10-25 2013-10-10 건국대학교 산학협력단 폐렴균점막다당질 유형14 （ｃｐｓ１４）와 호스래디시 퍼옥시다제의 당단백중합체
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
ES2993430T3 (en) 2014-11-21 2024-12-30 Univ Oklahoma Pneumolysin mutants and methods of use thereof
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
IL267709B2 (en) 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
MX2019014829A (es) 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3900739A1 (en) * 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US5192540A (en) * 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp Conjugate vaccine formed from a polysaccharide and a c protein of b-streptococcus
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines

Also Published As

Publication number Publication date
AU704450B2 (en) 1999-04-22
KR970705410A (ko) 1997-10-09
IL115047A (en) 2005-08-31
IL115047A0 (en) 1995-12-08
DE69519634D1 (de) 2001-01-18
EP0778781A1 (en) 1997-06-18
US5565204A (en) 1996-10-15
CA2198251C (en) 2007-06-12
JPH10504717A (ja) 1998-05-12
PT778781E (pt) 2001-03-30
DK0778781T3 (da) 2001-01-02
EP0778781B1 (en) 2000-12-13
JP3927233B2 (ja) 2007-06-06
DE69519634T2 (de) 2001-06-13
AU3363695A (en) 1996-03-14
KR100385411B1 (ko) 2003-12-11
WO1996005859A1 (en) 1996-02-29
ATE198051T1 (de) 2000-12-15
GR3035081T3 (en) 2001-03-30
CA2198251A1 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
ATE198051T1 (de) Pneumokokken-polysaccharid-rekombinante- pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen
CO2021008023A2 (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
DK0714444T3 (da) Dæmpning af en immundominant epitop i et antigen til anvendelse i plante-, dyre- og humanvacciner og immunbehandlinger
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
ES2121820T3 (es) Vacuna de conjugados de polisacaridos de neumococos.
ES2103827T3 (es) Vacuna muerta inactivada del mycoplasma hyopneumoniae y metodo de empleo de la misma.
DE68917126D1 (de) T-zellen-epitope als träger für einen konjugierten impfstoff.
PE20240927A1 (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
AR022965A1 (es) Vacuna
AR003006A1 (es) Composición de vacuna combinada que comprende un polisacarido capsular de haemophilus influenzae b conjugado con una proteina portadora adsorbido sobre fosfato de aluminio y uno u otros antígenos distintos, métodos para producirla, y su uso para preparar un medicamento
DK0754055T3 (da) Gruppe A-streptokok-polysaccharid-immunogen-præparater og metoder
TR199801722T2 (xx) Peptit imm�nojenler.
NO950739D0 (no) Vaksiner mot gruppe C Neisseria Meningtidis
ES2160601T3 (es) Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.
ES2126616T3 (es) Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna.
DK0636030T3 (da) Pasteurella haemolytica type A-1-bacterin-toxoid-vaccine
ES2102836T3 (es) El empleo de vacunas antihelminticas en el control de la enfermedad parasitaria asociada con la perdida de la inmunidad natural.
AR132428A1 (es) Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y usos de estos
CO5241277A1 (es) Vacuna
ES2059605T3 (es) Vacuna toxoide de la tosferina.
CO2025006472A2 (es) Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y sus usos
PE20251701A1 (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
CO2025013417A2 (es) Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y usos de estos
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 778781

Country of ref document: ES